Sung RJ et al. Mechanisms of spontaneous alternation between reciprocating tachycardia and atrial

flutter/fibrillation in the Wolff-Parkinson-White syndrome. Circulation. 1977;56:409.

Tijunelis MA et al. Myth: intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-ParkinsonWhite syndrome in the emergency department. CJEM. 2005;7:262–265.

Gulamhusein S et al. Acceleration of the ventricular response during atrial fibrillation in the Wolff-ParkinsonWhite syndrome after verapamil. Circulation. 1982;65:348.

Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter [published correction appears in Ann

Intern Med. 1992;117:446]. Ann Intern Med. 1992;117:141.

Aliot E et al. Twenty-five years in the making: flecainide is safe and effective for the management of atrial

fibrillation. Europace. 2010;13:161–173.

Krahn AD et al. A randomized, double-blind, placebo controlled evaluation of the efficacy and safety of

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.

124.

125.

intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome. Pacing Clin

Electrophysiol. 2008;24:1258–1260.

Cohen MI et al. PACES/HRS expert consensus statement on the management of the asymptomatic young

patient with a Wolff-Parkinson-White (WPW, Ventricular Preexcitation) Electrocardiographic pattern. Heart

Rhythm. 2012;9:1006–1024

Barra SN et al. A review on advanced atrioventricular block in young or middle-aged adults. Pacing Clin

Electrophysiol. 2012;35:1395–1405.

Pedersen CT et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm.

2014;11:e166–e196.

Majorowicz K. Clinical Management of Ventricular Arrhythmias. Sacramento, CA: CME Resource; 2008.

Cantillon DJ et al. Evaluation and management of premature ventricular complexes. Cleve Clin J Med.

2013;80:377–387.

Echt DS et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac

Arrhythmia Suppression Trial. N EnglJ Med. 1991;324:781.

[No authors listed]. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The

Cardiac Arrhythmia Suppression Trial II Investigators. N EnglJ Med. 1992;327:227.

Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the

postinfarction period. Am J Cardiol. 1997;80(9B):35J.

Freemantle N et al. Beta-blockade after myocardial infarction: systematic review and meta regression analysis.

BMJ. 1999;318:1730.

Kendall MJ et al. Beta-blockers and sudden cardiac death. Ann Intern Med. 1995;123:358.

[No authors listed]. Randomised trial of intravenous atenolol among 16, 027 cases of suspected acute myocardial

infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet. 1986;2:57.

Chen ZM et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction:

randomised placebo-controlled trial. Lancet. 2005;366:1622.

O’Gara PT et al. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction: a

report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice

Guidelines. J Am Coll Cardiol. 2013;61:e79–e140.

Caims JA et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive

ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial

Investigators [published correction appears in Lancet. 1997;349: 1776]. Lancet. 1997;349:675.

Julian DG et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular

dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarction Amiodarone Trial

Investigators [published corrections appear in Lancet. 1997;349:1776; Lancet. 1997;349:1180]. Lancet.

1997;349:667.

Buxton AE et al. Nonsustained ventricular tachycardia in coronary artery disease: relation to inducible sustained

ventricular tachycardia. MUSTT Investigators. Ann Intern Med. 1996;125:35.

Connolly SJ. Meta-analysis of antiarrhythmic drug trials. Am J Cardiol. 1999;84:90R–93RR.

Farre J et al. Amiodarone and “primary” prevention of sudden death: critical review of a decade of clinical trials.